European Commission approves Pfizer’s RSV vaccine ABRYSVO® to help protect adults aged 18-59 against RSV lower respiratory tract disease

Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication, which includes:

• Active immunization of individuals 18 years of age and older for the prevention of LRTD caused by RSV
• Passive…